دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
High-density lipoproteins, lipoprotein(a), and remnant cholesterol: new opportunities for reducing residual cardiovascular risk
Filippo Crea
doi : 10.1093/eurheartj/ehad224
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1379–1382
Iron deficiency in heart failure across the spectrum of left ventricular ejection fraction: dotting the i’s
Faro R Verelst, Emeline M Van Craenenbroeck, Andreas B Gevaert
doi : 10.1093/eurheartj/ehad131
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1383–1385
Reduced lean body mass: a potential modifiable contributor to the pathophysiology of heart failure
Candela Diaz-Canestro, Hung-Fat Tse, Kai-Hang Yiu, David Montero
doi : 10.1093/eurheartj/ehad130
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1386–1388
Putting young professionals at the heart of the cardiovascular community: Maria Rubini Gimenez, MD
Judith Ozkan
doi : 10.1093/eurheartj/ehad031
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1389–1391
Improving care for heart failure patients by COACHing clinicians to use decision-support tools
Daniela Pedicino, Massimo Volpe
doi : 10.1093/eurheartj/ehad097
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1392–1393
High-density lipoprotein revisited: biological functions and clinical relevance
Arnold von Eckardstein, Børge G Nordestgaard, Alan T Remaley, Alberico L Catapano
doi : 10.1093/eurheartj/ehac605
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1394–1407
Previous interest in high-density lipoproteins (HDLs) focused on their possible protective role in atherosclerotic cardiovascular disease (ASCVD). Evidence from genetic studies and randomized trials, however, questioned that the inverse association of HDL-cholesterol (HDL-C) is causal. This review aims to provide an update on the role of HDL in health and disease, also beyond ASCVD.
Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
Gregory G Schwartz, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Maja Bujas-Bobanovic, Rafael Diaz, Sergio Fazio, Zlatko Fras, Shaun G Goodman, Robert A Harrington, J Wouter Jukema, Garen Manvelian, Robert Pordy, Kausik K Ray, Michel Scemama, Harvey D White, Ph Gabriel Steg, for the ODYSSEY OUTCOMES Investigators
doi : 10.1093/eurheartj/ehad144
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1408–1417
Long-term, placebo-controlled cholesterol-lowering trials have demonstrated legacy effects (clinical benefits that persist or emerge after trial end). It is unknown whether legacy effects follow a short period of very low low-density lipoprotein cholesterol (LDL-C) levels achieved with statin plus proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.
Transient very low LDL-C levels: a legacy effect for cardiovascular prevention?
Jacques Genest
doi : 10.1093/eurheartj/ehad155
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1418–1420
Lipoprotein(a) levels in children with suspected familial hypercholesterolaemia: a cross-sectional study
Lotte M de Boer, Barbara A Hutten, Aeilko H Zwinderman, Albert Wiegman
doi : 10.1093/eurheartj/ehac660
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1421–1428
Familial hypercholesterolaemia (FH) predisposes children to the early initiation of atherosclerosis and is preferably diagnosed by DNA analysis. Yet, in many children with a clinical presentation of FH, no mutation is found. Adult data show that high levels of lipoprotein(a) [Lp(a)] may underlie a clinical presentation of FH, as the cholesterol content of Lp(a) is included in conventional LDL cholesterol measurements.
Lp(a): a genetic cause of clinical FH in children
Maurizio R Averna, Angelo B Cefalù
doi : 10.1093/eurheartj/ehac789
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1429–1431
Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality
Benjamin N Wadström, Kasper M Pedersen, Anders B Wulff, Børge G Nordestgaard
doi : 10.1093/eurheartj/ehac822
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1432–1445
Cholesterol carried in triglyceride-rich lipoproteins, also called remnant cholesterol, is being increasingly acknowledged as an important causal risk factor for atherosclerosis. Elevated remnant cholesterol, marked by elevated plasma triglycerides, is associated causally with an increased risk of atherosclerotic cardiovascular disease.
What is ‘remnant cholesterol’?
Paulina E Stürzebecher, Julius L Katzmann, Ulrich Laufs
doi : 10.1093/eurheartj/ehac783
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1446–1448
Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein
Peter E Thomas, Signe Vedel-Krogh, Pia R Kamstrup, Børge G Nordestgaard
doi : 10.1093/eurheartj/ehad055
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1449–1460
Recent evidence suggest that the lipoprotein(a)-associated risk of atherosclerotic cardiovascular disease (ASCVD) may be observed only in individuals with low-grade systemic inflammation. It was hypothesized that high lipoprotein(a) is a main driver for the risk of ASCVD, myocardial infarction, and aortic valve stenosis irrespective of C-reactive protein levels.
C-reactive protein in people with high lipoprotein a: a partner in crime or an innocent bystander?
Carl E Orringer
doi : 10.1093/eurheartj/ehad080
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1461–1463,
Long-term cardiometabolic health in people born after assisted reproductive technology: a multi-cohort analysis
Ahmed Elhakeem, Amy E Taylor, Hazel M Inskip, Jonathan Y Huang, Toby Mansell, Carina Rodrigues, Federica Asta, Sophia M Blaauwendraad, Siri E Håberg, Jane Halliday, Margreet W Harskamp-van Ginkel, Jian-Rong He, Vincent W V Jaddoe, Sharon Lewis, Gillian M Maher, Yannis Manios, Fergus P McCarthy, Irwin K M Reiss, Franca Rusconi, Theodosia Salika, Muriel Tafflet, Xiu Qiu, Bjørn O Åsvold, David Burgner, Jerry K Y Chan, Luigi Gagliardi, Romy Gaillard, Barbara Heude, Maria C Magnus, George Moschonis, Deirdre Murray, Scott M Nelson, Daniela Porta, Richard Saffery, Henrique Barros, Johan G Eriksson, Tanja G M Vrijkotte, Deborah A Lawlor
doi : 10.1093/eurheartj/ehac726
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1464–1473
To examine associations of assisted reproductive technology (ART) conception (vs. natural conception: NC) with offspring cardiometabolic health outcomes and whether these differ with age.
Reassurance for parents with children bornvia assisted reproductive technology or too soon to tell?
Claire M Lawley, Clare Arnott, Gemma A Figtree
doi : 10.1093/eurheartj/ehac827
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Pages 1474–1476
Candida endocarditis in a transcatheter aortic valve
Crystal B Chen, Harish Jarrett, Scott M Goldman
doi : 10.1093/eurheartj/ehad070
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Page 1477
Fatal infective endocarditis early after TAVR
Raluca Tomoaia, Irina Sandu, Ruxandra Ștefana Beyer
doi : 10.1093/eurheartj/ehad075
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Page 1478
Dynamic digital radiography: a novel quantitative modality to assess the pulmonary blood flow
Daisuke Toyomura, Kenichiro Yamamura, Yuzo Yamasaki
doi : 10.1093/eurheartj/ehad112
European Heart Journal, Volume 44, Issue 16, 21 April 2023, Page 1479
